- NewsCategory：
- All Company news Industry news
common105One result
-
1226
Bank of England Enhances Sc©σrutiny of Lloyd’s Whistleblower Systems
The Bank of England has steppφ₩'™ed up its monitoring&nbγ✘sp;of Lloyd’s of London’s whistleblowing systems,§λ♥♣ the central bank said on Monday, afte∞♠r reports this year about sexual harassεβment and bullyinα₩g at the 330-year old ins≥γδurance market.The Prude£€★€ntial Regulation Authority γ"(PRA) said the insurance&n≥"bsp;market had agreed to extra checks after inf↔♦orming the regulator its processes h♣ &™ad been ineffective.he PRA sai₽β© d it was first made aware of is>>sues at Lloyd’s in February when the market told →↕☆the regulator its only anony© ₩ mous whistleblowing channel for sta×≈ff had not been operatio≥ ✘§nal since October 2017.Other whistlebl ∞₹owing channels were available while the anony↑σ&mous hotline was down, the PR<A said.Lloyd’s also failed to p"<✔rovide an annual whistleblowing report as expect♠φΩed, the regulator added.Lloyd’s has voluntarily ♠₩agreed to additional requirements, including¶✘ enhanced reporting of whistle₽§blowing cases and training requireme÷÷₽nts for senior staff, the PRA s<"• aid.Following press reports of widespread m≠♣Ωisconduct at Lloyd’s, the market publishα≥✘ed results of a survey i₽•€n September that found "♣σ≤nearly one in 12 employees working in the ma₩≤ rket had witnessed seπε<¶xual harassment there in the past y'←ear, while a quarter had witnessed exces§×&sive drinking.Lloyd’s has tried to&nε&bsp;improve standards of bα☆ehavior in the mar"♣™ket this year, including introducing life≥ bans from its building and a bullying an®™∞✘d harassment hotline.The Lloyd’s market emplo<≥ys nearly 50,000 people anπ£≈d has 99 syndicate members o↑≤ffering insuran™✔≈ce in specialist areas from ships to sculp÷₹tures.“We are extremely disappointed by this faiβ≥lure in our internal controls, which serves to r∑± emind us all about the nee₹£d for constant vigilance when it comes t>≥<o these essential services,” a Lloyd’s sΩ> pokesman said.“Lloyd’s employees can fδδΩeel confident that we now have all the ± right mechanisms in place for th&πem to report any wrongdoing, and that the✔π se systems are regularly monitored.”(Reportin₽₽g by Iain Withers; editing by Louise H×÷eavens and Edmund Blair)From:insur$λ☆ance journalOrganizer：÷✘₩•China Insurance Digital & AI Developmentσ♥♦ 2020Web:http://en.zenseegroup.com/p/560©↓∏€573/Contact:Ann 021-65650305 -
0822
Tonix Pharmaceuticals Expan♥σds Preclinical Pipeline wi↔$₹§th Triple Reuptake Inhibitor, TNX-1600, for t↑≥ <he Treatment of PTSD
Tonix Pharmaceuticals Holding Corp., a cliniα&cal-stage biopharmaceutical company, announ©±ced today an exclusive agreement to in-li♦λ✘§cense a triple reuptake inhibitor★↕ (TRI), TNX-1600 (form↓↔erly D-578), to treat posttraumati≈>↔c stress disorder (PTSD>₹) and potentially other central nervous system ≤↔ (CNS) disorders. The compound wa±♣✔₩s developed and pharmacologically ↔≤characterized by Aloke Dutta, Ph.D₹γ., professor of Pharmaceutical Sciences a®<↕™t Wayne State University, with funding fro≈δm a National Institutes of Hea€↕€®lth grant (grant number →πγMH084888), and the pa™™tents covering the compoundσs were licensed to TRImaran Pharma, Inc. (TRImara↔δ¥n). The transaction announcedλ←∞ today is a license agreement w £↔←ith Wayne State and an asset acquisition with Tπ✔RImaran.“We are excited to expand ourφ₹∏ pipeline and are lo→♦✘±oking forward to developing TNX-1600 as a potent₩≤ ial treatment for PTSD,” said Seth Leder♦£man, M.D., Tonix's President and Chief Execu∞©tive Officer. “We plan to ≈↕∑≤utilize our clinical exper₩±ience in PTSD to evaluate tα¶he therapeutic benefit of TNX-★λβ1600. PTSD is a heterog≠φφeneous condition, so we believe d↕'±"ifferent PTSD patients may δ¶α≈respond to different medicines. In some cases, mo÷↓re than one drug will be re&§✘quired for effective treatment. TNX"↓β-1600 is our third drug candidate in developmeφ♥λnt for PTSD. Our most advanced φ®∏≥candidate is TNX-102 SL£♦φ♣, which is in Phase 3 dφ↓✔evelopment. We are also devel✔✘oping TNX-601 which is entering a ♠♣≤↑Phase 1 trial imminently. TNX-16•γ♣ε00 is in the pre-IND phase of dσ§evelopment with encouraging data from animal mod™®←↓els of PTSD.”Frank Bymas∑ter, Chief Scientific Officer and co-'< λfounder of TRImaran Pha★♦★§rma Inc. said, “TNX-1α 600 is a novel TRI that inhibits simultaneouslγ§y the reuptake of th☆±♠ree key neurotransmitters: serotonin, noreσ≤pinephrine and dopamine. Each of these three n >←eurotransmitters plays a key modulatory≥¶ role in many CNS processes. Inhibiting₩φ reuptake of all three may provide an effec ₩¥÷tive treatment for PTSD.”According to Dr. Alok₹≥e Dutta, “We have developed an in∏©εφnovative triple reuptake inhib©÷&itor, D-578, based on a unique pyran molecΩ©→>ular scaffold to address the current thera≤ γ•peutic needs for PTSD and o→βther neurological disorders. Ba£→γ<sed on our preliminary data, we expect a π">pharmacological synergy from their potent €✘modulatory effect on the leve >♦l of monoamine neurotransmitterγ₽s in the brain which shoΩαuld facilitate effective treatment of ♣§™these disorders.”Under the terms of the agreementβφ, Tonix has been granted an exclusive lic ense from Wayne State University for♥₩ £ technology and patents related &©→¥to TNX-1600 and other ♠÷pyran-based compounds. Anoth±★er member of the class, D'→ ¥-473, has also shown effect≤♥$s in a rodent model of depression.the 2019 Asi&•a-pacific Pharmaceutical IP Lead>↔er Summit will be held in Beijing on November 1λ€4-15, and will attract more than 500 industry λ★±experts from domestic and foreign pharmaceu♥∑↔tical companies, biotechnologyφ★ companies, governments, assocφ®iations, law firms, intellectual property age<λnts and other companies to attend. 2">019 Asia-pacific Pharmaceutical IP ≠Leader Summit Official registr₽₩ ation and consultation ×σπchannels:Contact：AnnPhoγ ε☆ne: 021-65650305Email：Marketinφφσg@zenseegroup.comhttp://en.zenseegroup.com/p≠$©/510934/ -
1225
Health Provider in Arizona to P®βay $6M Settlement in Bβ↕reach
A Phoenix, Ariz.-based health provider haλ₩s agreed to settle a lawsuit•< over a computer dataקα breach that may hav₽↓αe compromised health and '™Ωpersonal data of about 3 million patie∞&nts, employees, health insurance custom> ers and others.The class action lawsuit agains∏>±≤t Banner Health stemmed from a 2>016 cyberattack that exposed α↔the information, The Arizo±±∞na Republic reports.The settlement, up to ∏♠♠$6 million, includes free insurance coverag≠•δ₩e for claims of up to $1 million✘π to cover financial losses and two years of f εree credit monitoring through Identity '&γ✘Guard Total, officials said.When the breach€♥ occurred, Banner Health i≈≈≥nitially gave those affect®↓↔ed a year of free credit monitoring, officials s≥↓aid.Those affected would be able to file claimπ✔&φs for up to $500 for ordinary expenses or up to ε $10,000 for extraordin≈♠ ary expense reimbursement such as lost time at§φ work or professional help with identity thδ★eft issues under the settlement ♦ agreement, company officials≤φ≤ said.“All things considered®<', this settlement compares very favorably with ≈>those that have beenβ₹♥ approved in other data breach cases,” sa★δ←λid Andrew Friedman, one of t≠§π₽he lawyers representing the plaintiff↓↔s.The settlement was granted preliminar♠∏©y approval and is subject to final court apprπ•oval April 21, officials said.“This is still㶥 a pending legal matter, so we are unable to discuss detailπ☆>s. However, we are hopeful ♠♣ that it will be resolved soon, at which $Ωtime those who were impacted ca↕ελn learn additional information,” provideΩβ♣r spokeswoman Becky Armendariz s♠<€λaid.Banner Health has also agreed to iγ§mprove its information securπ★¥εity systems, officials s♣§✔≤aid.“In the meantime, data securitλ↔₩y is one of our highest pr↓↑↓iorities and we continue to work diligently t'≠o protect the sensitive information of∏ our patients and emα'≥ployees,” officials said.From:insurance journa±★÷♥lOrganizer：China Insurance Digital & AI∞××↔ Development 2020Web:http://en.zense ¶egroup.com/p/560573/Contact:Ann 021-6565≤↓0305 -
0821
Moderna Receives FDA ∞αFast Track Designation for ZikΩ♣λa Vaccine mRNA-1893
Moderna, Inc., a clinical stage biotechnoloλα•gy company pioneering messenger RNA (mR>♣↑ΩNA) therapeutics and vaccines to create a ne"£w generation of transfo≠•rmative medicines for patients, ∏>₹today announced that the U.S. Food and₽♣↕ Drug Administration (FDA) has gra₩$nted Fast Track designation for its inve♥★Ωstigational Zika vaccine (mRNA-1893) curren€ ≠tly being evaluated in a Phase 1 s♦β≥tudy for the prevention of Zika viφβ rus infection in healthy adults.Fas©₹t Track is designed to facilitate™ the development and expedλδ↕ite the review of therapies and vaccines f∏$↓or serious conditions and fill an unmφ•et medical need. Progra↑₽ ms with Fast Track desig>∞nation may benefit from early and fr•♣equent communication with the FDA, in addition≠$✘ to a rolling submissi&©on of the marketing application. Moderna $♣•✘previously received Fast Tra™♥ck designation for its methylmalonic aci♣φdemia (MMA) program (mRNA-3704), which is φ®now recruiting patientsφ for a Phase 1/2 clinical study.“Protecπ×♠ting against Zika virus transmission, particα•εularly in women during prγγegnancy, continues to ♦§be an area of high unmet need. Fast Track ±™≤designation supports our belief in the clπδ>inical potential of mRNA-1893 and the importance φ ≠ of developing an effective vaccine that can β♣be rapidly developed and deployed±π★',” said Tal Zaks, M.D., Ph.D., chief medical of♦♣ficer at Moderna. “Our Zika program ♣₽is part of Moderna’s broader commi≤♦©≤tment to improving glob'↓al public health through d€λ ≈eveloping mRNA vaccines to p•revent the spread of infecti&$←ous diseases.”mRNA-1893 contains an mRNαδA sequence encoding for the sΩ♦₽tructural proteins of Zika virus and is deβφ> signed to cause cells to secrete virus-like λε←particles, mimicking t™Ω≈↕he response of the cell after naλ™♥εtural infection. Preclinic÷≤±al data published in The Journ¶¥π★al of Infectious Dis屩eases have shown that★β vaccination with mRNA-1893 protected aga★✔φinst transmission of Zika v©& irus during pregnancy in mic☆≤÷∏e.1 mRNA-1893 is currently in a Phase 1 ><→study evaluating safety, phφ®armacokinetics and pharmacody€λ₽namics in healthy voluntee≥≠rs.This project has been funded in whole or in↑∏© part with Federal funds¥∏ from the Department of Health and Hum→ an Services (HHS); Office of the Assistant Secre₹♣✔tary for Preparedness and Response; Biom÷ 'edical Advanced Research and Development Au≤¥εthority (BARDA), under Con"≤₩<tract No. HHSO100201600029C.from--Pha>πrma Focus AsiaIn recent years, the siz∞★α e of the global pharmaceutical market has mai≠σ₽ntained a steady growth, with Chi∏☆<na, South Korea, India and other emergi✔"∑ng markets presenting a rapid growth momentu™λm. Due to the different intelle £≠ctual property policies of di★σfferent countries, th≤Ω★e strategic layout of global intellectual pr>♠operty, the differences of pharmaceutical inα♠÷tellectual property ≥•δ₹policies of Asia-paciε★fic countries, the patent review proces≠s, litigation procedures and Generic drug patent©× strategy have gradually become the hot sp÷§↑♣ots of the pharmaceutical iε£€ntellectual property industry.&nbεδ ±sp;In this context, the 2019 Asia-pacific Pharma₩≤ceutical IP Leader Summit will be held in λ← δBeijing on November 14-15, and®←β> will attract more than 500→≥ industry experts from domestic and foreign ≤Ωpharmaceutical companies, biotechnology compan×λ₹ies, governments, associations, law firms,≈₩ intellectual property agents and other companie♠♦"↕s to attend.2019 Asia-pacific pharm ★δa IP Leader Summit Official registr→₽→∏ation and consultation c→<☆✘hannels:Contact：AnnPhone: 021-65650305E★¥¶mail：Marketing@zenseegroup.com -
1224
AXA XL, Slice Labs, Microsoft to Offer Cyb ε§er Risk Management Tools
From:insurance journalAXAΩ≈ XL, the p&c and®→§ Specialty Risk Division of global insurer A¶πXA, Slice Labs Inc. (Slice), an on-dem✔₹<and insurer of cloud≤§ technology, and Microsoft wi♦φll work together to ∞Ωhelp improve cyber health an₹∑d mitigate risks for Microsoft 365 Business,≥★ Office 365 Business Premium and Offε≥®ice 365 Business customers. The new r₹βσδelationship will give q↔₽ualifying customers discounted acce≈•$©ss to Slice on-demand, cloud-based c♥ε✔yber insurance provided by AXA X≥≤L.Microsoft customers will have access to an δαend-to-end product that will help them λγsecure their environment an↑¥d give them the critical services and sup§port for incident response and remediatio÷n in the event of a ♣≠€•successful cyber-attack. These servic₩§♣es are all part of AXA XL’s cyber insurance p♦↓olicy, which will be offered at>"γ discounted pricing to qualified custo☆♦× mers who represent a lower insurance risk base↑←α✔d on a security posture asσ₹sessment that will be provided by Microsoft$ Secure Score.Recent Forre¥®¥λster survey results foun×ε☆↔d that cybersecurity aΩ πttacks are a business reality for small and mid-§size businesses (SMBs), with nearly half뱩→ having had a breach wit∏hin the last year. WhatΩ≈↕± was more concerning was that 27% of SMBs w↔>§ere unaware if they’ve had a bre↔>ε↓ach. One primary issue is∑φ that 58% of the SMBs str≥ ∞↕uggle to maintain basic cybe♦∑rsecurity hygiene.“This nσ♠ew level of integration wit¶σh Microsoft and Slic£©e Labs reinforces the faφ®ct that insurance is no longer a♣♣n after the fact product that companiγ✘∞♣es should use as a band-aid when an incident occu✔®₹rs,” said John Coletti, Chief Under∏ writing Officer, AXA XL’s cyber insuranc©≥∏<e team in North America.Small business Mic≥Ω'rosoft customers can access AXA XL Cyber I₩×nsurance offered by Slice&nb >♦÷sp;here.Slice Labs is the insuran₩©βce engine behind tomorrow’s cloud-based, on-dema♠Ω>∑nd digital services $ecosystems for the new economy. Through Sli☆φ§ce’s Insurance Cloud Serv≠•ices (ICS) platform, Slice is enabling in±φsurers, technology companies, an♦←d other service providers to build pay-as-y☆↕ou-go digital insurance pro$σ↓ducts protecting the insured anytime a< nd anywhere. Slice is lic•σ™§ensed in the US and✘☆ the UK.Organizer：China↓≈" Insurance Digital & AI Develop"♥ ment 2020Web:http://en.zenseegroup.com/p/560573→≥✔/Contact:Ann 021-65650305
Contact Us
Zensee_Daystar online
© 2011-2016